Abstract
In a controlled study, Greenberg's staphylococcal polyvalent somatic antigen vaccine was administered to 190 Indian volunteers of a reserve in Saskatchewan in an attempt to reduce the incidence of impetigo. An intradermal skin test dose of 0.1 ml. was given initially. Reactors were forthwith placed in a separate category, otherwise this test injection was followed by intramuscular injection of 0.25 ml. of the vaccine, repeated a second time after six weeks. One hundred and sixty-nine controls received “placebo vaccine”. Four months later the number of cases of impetigo in the vaccinated group had been reduced from 55 to 16. There was no reduction in the control group. The preventive effect waned after five months. The results of this field trial are considered encouraging.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- GREENBERG L., COOPER M. Y., HEALY G. M. Staphylococcus polyvalent somatic antigen vaccine. II. An improved method of preparation. Can Med Assoc J. 1961 Apr 29;84:945–947. [PMC free article] [PubMed] [Google Scholar]
- GREENBERG L., COOPER M. Y. Polyvalent somatic antigen for the prevention of staphylococcal infection. Can Med Assoc J. 1960 Jul 23;83:143–147. [PMC free article] [PubMed] [Google Scholar]
- GREENBERG L., LE RICHE W. H. Staphylococcal enzyme lysed soluble vaccine. Can J Public Health. 1961 Nov;52:479–485. [PubMed] [Google Scholar]